Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study (CERTAIN)
9. desember 2011 oppdatert av: UCB Pharma
A Phase IIIB, Multi-center, Double-blind, Placebo-controlled, Parallel Group, 52-week Study to Evaluate the Safety and Efficacy of Certolizumab Pegol, Administered With DMARDs, in Patients With Low to Moderate Disease Activity Rheumatoid Arthritis
To assess the clinical efficacy and safety of certolizumab pegol as add-on therapy with stable-dose disease-modifying antirheumatic drugs (DMARDs) for achieving clinical remission in patients with moderate to low disease activity rheumatoid arthritis
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Treatment period starts with a 24-week, double blind, placebo-controlled, randomized period followed by an open label phase until week 52.
In the double blind phase eligible patients will be randomized via an Interactive Voice Response System (IVRS) in a 1:1 ratio to receive either certolizumab pegol (400 mg at Weeks 0, 2 and 4, followed by 200 mg every two weeks) or placebo up to and including Week 22. All patients will continue to receive their Disease Modifying AntiRheumatic Drugs (DMARDs) therapy established before study entry until Week 52. At Week 24, patients will not receive any injection but will be evaluated:
- Non-remitters at Week 24 (patients who did not achieve remission at both Week 20 and Week 24) will be discontinued from the study and may be given the opportunity to enter in an open-label follow-up trial, C87080 [NCT00843778], with certolizumab pegol.
- Remitters (i.e. patients who achieved remission as measured by Clinical Disease Activity Index (CDAI) at both Week 20 and Week 24) will stop their randomized treatment (certolizumab pegol or placebo) and be followed up until Week 52. Remitters who flare up (CDAI ≥11 confirmed at two consecutive visits four weeks apart) between Week 24 and Week 52 will be re-treated with the same dosing regimen of certolizumab pegol (3 administrations of 400mg, given every 2 weeks, followed by 200 mg given every other week) up to and including Week 50.
Remitters who flare up between Week 24 and Week 52 and complete 52-week study period will be allowed to enter open label follow up trial at Week 52.
Studietype
Intervensjonell
Registrering (Faktiske)
194
Fase
- Fase 3
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Nantes, Frankrike
-
Paris, Frankrike
-
Rennes, Frankrike
-
Rouen, Frankrike
-
Tours, Frankrike
-
-
-
-
-
Ferrara, Italia
-
Padova, Italia
-
Pavia, Italia
-
Roma, Italia
-
-
-
-
-
Bialystok, Polen
-
Bydgoszcz, Polen
-
Elblag, Polen
-
Lublin, Polen
-
Poznan, Polen
-
Sopot, Polen
-
Szczecin, Polen
-
Torun, Polen
-
Wroclaw, Polen
-
-
-
-
-
Bad Nauheim, Tyskland
-
Berlin, Tyskland
-
Erlangen, Tyskland
-
Essen, Tyskland
-
Frankfurt, Tyskland
-
Hamburg, Tyskland
-
Heidelberg, Tyskland
-
Herne, Tyskland
-
Ratingen, Tyskland
-
Vogelsang-Gom, Tyskland
-
Wurzburg, Tyskland
-
-
-
-
-
Graz, Østerrike
-
Wien, Østerrike
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Patients with established diagnosis of low to moderate adult rheumatoid arthritis, currently on Disease Modifying AntiRheumatic Drugs (DMARDs) therapy for at least six months and not longer than 10 years
Exclusion Criteria:
- All the concomitant diseases or pathological conditions that could interfere and impact the assessment of the study treatment, or with the safety of the patient
- Previous clinical trials and previous biological therapy that could interfere with the results in the present clinical trial
- Patients must not have received any previous biological therapy for rheumatoid arthritis (RA)
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Certolizumab pegol 200 mg (CDP870)
Two 200 mg subcutaneous injections at Week 0, Week 2, and Week 4 followed by 200 mg injections every 2 weeks until the last drug administration (Week 22)
|
Two 200 mg subcutaneous injections at Week 0, Week 2, and Week 4 followed by 200 mg injections every 2 weeks until the last drug administration (Week 22)
Andre navn:
|
|
Placebo komparator: Placebo
Two 0.9% saline subcutaneous injections at Week 0, Week 2, and Week 4 followed by 0.9% saline injections every 2 weeks until the last drug administration (Week 22)
|
Two 0.9% saline subcutaneous injections at Week 0, Week 2, and Week 4 followed by 0.9% saline injections every 2 weeks until the last drug administration (Week 22)
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Clinical Disease Activity Index (CDAI) Remission (≤2.8) at Both Week 20 and Week 24
Tidsramme: Week 20 and Week 24
|
CDAI is calculated as the sum of tender joint count (TJC), swollen joint count (SJC), Patient's Global Assessment of Disease Activity - Visual Analog Scale (PtGADA-VAS in cm), and Physician's Global Assessment of Disease Activity - Visual Analog Scale (PhGADA-VAS in cm).
28 joints are examined where a lower score indicates less disease activity.
Missing values were imputed using Non-Responder Imputation (NRI)
|
Week 20 and Week 24
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
28-joint Count Disease Activity Score (DAS28-ESR) Remission (<2.6) at Both Week 20 and Week 24
Tidsramme: Week 20 and Week 24
|
DAS28-ESR is calculated using the tender joint count (TJC), swollen joint count (SJC) erythrocyte sedimentation rate (ESR in mm/hour), and the Patient's Global Assessment of Disease Activity - Visual Analog Scale (PtGADA-VAS in mm) using the following formula: 0.56 x √(TJC) + 0.28 x √(SJC) + 0.70 x lognat (ESR) + 0.014 x Patient Global Assessment of Arthritis where 28 joints are examined and a lower score indicates less disease activity.
Missing values were imputed using Non-Responder Imputation (NRI)
|
Week 20 and Week 24
|
|
Simplified Disease Activity Index (SDAI) Remission (≤3.3) at Both Week 20 and Week 24
Tidsramme: Week 20 and Week 24
|
SDAI is calculated as the sum of tender joint count (TJC), swollen joint count (SJC), C-reactive protein (CRP in mg/dL), Patient's Global Assessment of Disease Activity - Visual Analog Scale (PtGADA-VAS in cm), and Physician's Global Assessment of Disease Activity - Visual Analog Scale (PhGADA-VAS in cm).
28 joints are examined where a lower score indicates less disease activity.
Missing values were imputed using Non-Responder Imputation (NRI)
|
Week 20 and Week 24
|
|
Time From Stopping Treatment (Week 24) to Loss of Remission (up to Week 52) Assessed Using Clinical Disease Activity Index (CDAI) Scores at 2 Consecutive Visits
Tidsramme: Week 24 up to Week 52
|
CDAI is calculated as the sum of tender joint count (TJC), swollen joint count (SJC), Patient's Global Assessment of Disease Activity - Visual Analog Scale (PtGADA-VAS in cm), and Physician's Global Assessment of Disease Activity - Visual Analog Scale (PhGADA-VAS in cm).
28 joints are examined where a lower score indicates less disease activity.
Patients losing remission (CDAI >2.8) for two consecutive visits will be considered as having the event on the day of the visit where remission was first lost.
Subjects discontinued/non-remitted by Week 24 are considered as having the event on day 1.
|
Week 24 up to Week 52
|
|
Time From Stopping Treatment (Week 24) to Loss of Remission (up to Week 52) Assessed Using Simplified Disease Activity Index (SDAI) Scores at 2 Consecutive Visits
Tidsramme: Week 24 up to Week 52
|
SDAI is calculated as the sum of tender joint count (TJC), swollen joint count (SJC), C-reactive protein (mg/dL), Patient's Global Assessment of Disease Activity - Visual Analog Scale (PtGADA-VAS in cm) and Physician's Global Assessment of Disease Activity (PhGADA-VAS in cm).
28 joints are examined.
A lower score indicates less disease activity.
Patients losing remission (SDAI >3.3) for two consecutive visits will be considered as having the event on the day of the visit where remission was first lost.
Subjects discontinued/non-remitted by Week 24 are considered as having the event on day 1.
|
Week 24 up to Week 52
|
|
Time From Stopping Treatment (Week 24) to Loss of Remission (up to Week 52) Assessed Using DAS28-ESR Scores at 2 Consecutive Visits
Tidsramme: Week 24 up to Week 52
|
DAS28-ESR is calculated using tender joint count (TJC), swollen joint count (SJC), erythrocyte sedimentation rate (ESR mm/hour) and Patient's Global Assessment of Disease Activity - Visual Analog Scale (PtGADA-VAS mm).
0.56x√(TJC) + 0.28x√(SJC) + 0.70xlognat(ESR) + 0.014xPtGADA-VAS.
28 joints are examined.
Lower score indicates less disease activity.
Patients losing remission (DAS28-ESR≥2.6)
for two consecutive visits will be considered as having the event on the first of the two visits.
Subjects discontinued/non-remitted by Week 24 are considered as having the event on day 1.
|
Week 24 up to Week 52
|
|
American College of Rheumatology 20% (ACR20) Response at Week 24
Tidsramme: Baseline, Week 24
|
ACR20 responders are subjects with at least 20% improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) Health Assessment Questionnaire-Disability Index (HAQ-DI), 2) C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale, 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale, 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale.
Missing values were imputed using Non-Responder Imputation (NRI)
|
Baseline, Week 24
|
|
American College of Rheumatology 50% (ACR50) Response at Week 24
Tidsramme: Baseline, Week 24
|
ACR50 responders are subjects with at least 50% improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) Health Assessment Questionnaire-Disability Index (HAQ-DI), 2) C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale, 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale, 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale.
Missing values were imputed using Non-Responder Imputation (NRI)
|
Baseline, Week 24
|
|
American College of Rheumatology 70% (ACR70) Response at Week 24
Tidsramme: Baseline, Week 24
|
ACR70 responders are subjects with at least 70% improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) Health Assessment Questionnaire-Disability Index (HAQ-DI), 2) C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale, 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale, 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale.
Missing values were imputed using Non-Responder Imputation (NRI)
|
Baseline, Week 24
|
|
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 24
Tidsramme: Baseline, Week 24
|
HAQ-DI is derived based on the mean of individual scores in 8 categories of daily living actives (using 20 questions).
Each question is scored 0-3 (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do).
Change from Baseline is computed as the value at Week 24 minus the Baseline value.
A negative value in change from Baseline indicates an improvement.
This analysis was carried out using the Last Observation Carried Forward (LOCF) method.
|
Baseline, Week 24
|
|
Change From Baseline in Short Form 36-items Health Survey (SF-36) Physical Component Summary (PCS) Scores at Week 24
Tidsramme: Baseline, Week 24
|
PCS norm-based scores are calculated based upon the following 8 domain scores, Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health, and range from 1 to 81, where 50 represents the normative value.
A larger positive value in change from Baseline indicates an improvement.
|
Baseline, Week 24
|
|
Change From Baseline in Short Form 36-items Health Survey (SF-36) Mental Component Summary (MCS) Scores at Week 24
Tidsramme: Baseline, Week 24
|
MCS norm-based scores are calculated based upon the following 8 domain scores, Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health, and range from -9 to 82, where 50 represents the normative value.
A larger positive value in change from Baseline indicates an improvement
|
Baseline, Week 24
|
|
Change From Baseline in Short Form 36-items Health Survey (SF-36) Physical Functioning Domain at Week 24
Tidsramme: Baseline, Week 24
|
There are 8 SF-36 domain scores: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health, each ranging from 0 to 100, with higher scores indicating better health.
A larger positive value in change from Baseline indicates an improvement
|
Baseline, Week 24
|
|
Change From Baseline in Short Form 36-items Health Survey (SF-36) Role Physical Domain at Week 24
Tidsramme: Baseline, Week 24
|
There are 8 SF-36 domain scores: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health, each ranging from 0 to 100, with higher scores indicating better health.
A larger positive value in change from Baseline indicates an improvement
|
Baseline, Week 24
|
|
Change From Baseline in Short Form 36-items Health Survey (SF-36) Bodily Pain Domain at Week 24
Tidsramme: Baseline, Week 24
|
There are 8 SF-36 domain scores: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health, each ranging from 0 to 100, with higher scores indicating better health.
A larger positive value in change from Baseline indicates an improvement
|
Baseline, Week 24
|
|
Change From Baseline in Short Form 36-items Health Survey (SF-36) General Health Domain at Week 24
Tidsramme: Baseline, Week 24
|
There are 8 SF-36 domain scores: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health, each ranging from 0 to 100, with higher scores indicating better health.
A larger positive value in change from Baseline indicates an improvement
|
Baseline, Week 24
|
|
Change From Baseline in Short Form 36-items Health Survey (SF-36) Vitality Domain at Week 24
Tidsramme: Baseline, Week 24
|
There are 8 SF-36 domain scores: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health, each ranging from 0 to 100, with higher scores indicating better health.
A larger positive value in change from Baseline indicates an improvement
|
Baseline, Week 24
|
|
Change From Baseline in Short Form 36-items Health Survey (SF-36) Social Functioning Domain at Week 24
Tidsramme: Baseline, Week 24
|
There are 8 SF-36 domain scores: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health, each ranging from 0 to 100, with higher scores indicating better health.
A larger positive value in change from Baseline indicates an improvement
|
Baseline, Week 24
|
|
Change From Baseline in Short Form 36-items Health Survey (SF-36) Role Emotional Domain at Week 24
Tidsramme: Baseline, Week 24
|
There are 8 SF-36 domain scores: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health, each ranging from 0 to 100, with higher scores indicating better health.
A larger positive value in change from Baseline indicates an improvement
|
Baseline, Week 24
|
|
Change From Baseline in Short Form 36-items Health Survey (SF-36) Mental Health Domain at Week 24
Tidsramme: Baseline, Week 24
|
There are 8 SF-36 domain scores: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health, each ranging from 0 to 100, with higher scores indicating better health.
A larger positive value in change from Baseline indicates an improvement
|
Baseline, Week 24
|
|
Change From Baseline in Patient's Assessment of Arthritis Pain-Visual Analog Scale (VAS) at Week 24
Tidsramme: Baseline, Week 24
|
Change from Baseline in Patient's Assessment of Arthritis Pain-VAS (0 to 100 mm visual analog scale, 0 being no pain and 100 being most severe pain) is computed as the value at Week 24 minus the Baseline value.
A negative value in change from Baseline indicates an improvement.
This analysis was carried out using the Last Observation Carried Forward (LOCF) method.
|
Baseline, Week 24
|
|
Change From Baseline in Patient's Global Assessment of Disease Activity - Visual Analog Scale (PtGADA-VAS) at Week 24
Tidsramme: Baseline, Week 24
|
Change from Baseline in Patient's Global Assessment of Disease Activity-VAS (0 to 100 mm visual analog scale, 0 being no symptoms and 100 being severe symptoms) is computed as the value at Week 24 minus the Baseline value.
A negative value in change from Baseline indicates an improvement.
This analysis was carried out using the Last Observation Carried Forward (LOCF) method.
|
Baseline, Week 24
|
|
Change From Baseline in Fatigue Assessment Scale at Week 24
Tidsramme: Baseline, Week 24
|
Change from Baseline in Fatigue Assessment scale (0 to 10, 0 is "No Fatigue" and 10 is "Fatigue as bad as you can imagine") is computed as the value at Week 24 minus the Baseline value.
A negative value in change from Baseline indicates an improvement.
This analysis was carried out using the Last Observation Carried Forward (LOCF) method.
|
Baseline, Week 24
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Time From Stopping Treatment (Week 24) to First Flare (up to Week 52) Using Clinical Disease Activity Index (CDAI) at 2 Consecutive Visits
Tidsramme: From Week 24 up to Week 52
|
Subjects having a flare (CDAI ≥11) between Week 24 and Week 52 for two consecutive visits will be considered as having the event on the day of the visit where flare first appeared.
|
From Week 24 up to Week 52
|
|
Association Between Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) Activity States at Week 24
Tidsramme: Week 24
|
The number representing the association is the Kappa Correlation Coefficient for CDAI/SDAI for each category of activity (Low Disease Activity (LDA) vs. non-LDA, Medium Disease Activity (MDA) vs. non-MDA, and High Disease Activity (HDA) vs. non-HDA).
|
Week 24
|
|
Association Between Clinical Disease Activity Index (CDAI) and Disease Activity Score (DAS28-ESR) Activity States at Week 24
Tidsramme: Week 24
|
The number representing the association is the Kappa Correlation Coefficient for CDAI/DAS28-ESR for each category of activity (Low Disease Activity (LDA) vs. non-LDA, Medium Disease Activity (MDA) vs. non-MDA, and High Disease Activity (HDA) vs. non-HDA).
|
Week 24
|
|
Association Between Disease Activity Score (DAS28-ESR) and Simplified Disease Activity Index (SDAI) Activity States at Week 24
Tidsramme: Week 24
|
The number representing the association is the Kappa Correlation Coefficient for DAS28-ESR/SDAI for each category of activity (Low Disease Activity (LDA) vs. non-LDA, Medium Disease Activity (MDA) vs. non-MDA, and High Disease Activity (HDA) vs. non-HDA).
|
Week 24
|
|
Association Between Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) Remission at Week 24
Tidsramme: Week 24
|
The number representing the association is the Kappa Correlation Coefficient for CDAI/SDAI remission.
|
Week 24
|
|
Association Between Clinical Disease Activity Index (CDAI) and Disease Activity Score (DAS28-ESR) Remission at Week 24
Tidsramme: Week 24
|
The number representing the association is the Kappa Correlation Coefficient for CDAI/DAS28-ESR remission
|
Week 24
|
|
Association Between Disease Activity Score (DAS28-ESR) and Simplified Disease Activity Index (SDAI) Remission at Week 24
Tidsramme: Week 24
|
The number representing the association is the Kappa Correlation Coefficient for DAS28-ESR/SDAI remission.
|
Week 24
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Hjelpsomme linker
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. juni 2008
Primær fullføring (Faktiske)
1. mai 2010
Studiet fullført (Faktiske)
1. desember 2010
Datoer for studieregistrering
Først innsendt
5. mai 2008
Først innsendt som oppfylte QC-kriteriene
6. mai 2008
Først lagt ut (Anslag)
7. mai 2008
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
18. januar 2012
Siste oppdatering sendt inn som oppfylte QC-kriteriene
9. desember 2011
Sist bekreftet
1. desember 2011
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- C87076
- 2007-000828-40 (EudraCT-nummer)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Certolizumab pegol
-
UCB PharmaTilbaketrukket
-
Nathan Wei, MD, FACP, FACR:University of California, San DiegoFullførtLeddgiktForente stater
-
UCB PharmaFullført
-
Atlanta Gastroenterology AssociatesUCB PharmaUkjent
-
UCB Pharma SAFullførtCrohns sykdomForente stater, Australia, Østerrike, Hviterussland, Belgia, Bulgaria, Canada, Tsjekkia, Danmark, Estland, Tyskland, Ungarn, Israel, Italia, New Zealand, Norge, Polen, Den russiske føderasjonen, Serbia, Singapore, Slovenia, Sør-Afrika, Span... og mer
-
University of WashingtonUniversity of Pennsylvania; UCB PharmaFullført
-
UCB PharmaFullførtLeddgiktDanmark, Nederland, Polen, Sverige
-
UCB PharmaTilbaketrukket